Categories
Archives
Receive Email Updates
-
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Tag Archives: s. 112
Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear
While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading
American Axle & Manufacturing v. Neapco Holdings–Part II
In my first post on American Axle’s Petition for cert., I focused on the substantive arguments of the parties. Almost as interesting is Part 5 of the Petition, in which AA argues that this is a good case for the … Continue reading
American Axle Petitions for Cert.
You may have noticed that I haven’t been posting since November. I feel like IP law has hunkered down and I find spats over jurisdiction and even the appeal urging the S. Ct. to validate IPR judgeships to be less … Continue reading
AAM v. Neapco – Part IV – Petition for Rehearing En Banc Denied – “Bad Vibrations”
This post will briefly discuss the Fed. Cir.’s denial of rehearing en banc – which left the modified panel opinion stand. The lengthy panel opinion has been the subject of my last three posts, and you should read them before … Continue reading
Posted in Patent Eligible Subject Matter
Tagged s. 101, s. 112, The State of Patent Eligibility
Leave a comment